A 58-year-old woman with type 2 diabetes and CKD stage 3b (eGFR 38 mL/min/1.73 m²) is already on metformin (dose-reduced) and empagliflozin. Her HbA1c is 8.2%. Per ADA 2024 guidelines, which additional agent is preferred for further glycemic and cardiorenal protection in this patient?
- A Sitagliptin
- B Semaglutide (GLP-1 receptor agonist) ✓
- C Pioglitazone
- D Glimepiride
Explanation
ADA 2024 guidelines recommend GLP-1 receptor agonists with proven cardiovascular benefit (semaglutide, liraglutide, dulaglutide) as preferred add-on agents in patients with CKD and established cardiovascular disease or high CV risk, even on an SGLT2 inhibitor. Semaglutide (oral or subcutaneous) is preferred as it also reduces cardiovascular events and slows kidney disease progression per the FLOW trial (2024). Sitagliptin has neutral CV and renal effects. Glimepiride carries hypoglycemia risk and has no cardiorenal benefit. Pioglitazone causes fluid retention worsening CKD.
Reference: Harrison's Principles of Internal Medicine, 21st ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.